Intest Res.
2018 Jul;16(3):499-501. 10.5217/ir.2018.16.3.499.
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
- Affiliations
-
- 1IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan.
- 2Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
- 3Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
- 4Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 5Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea.
- 6Inflammation & Immunology, Pfizer Japan Inc, Tokyo, Japan.
- 7Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, Japan.
- KMID: 2417664
- DOI: http://doi.org/10.5217/ir.2018.16.3.499
Abstract
- The authors regret an error in the reporting of Inflammatory Bowel Disease Questionnaire (IBDQ) patient-reported outcome data in the manuscript. A data extraction error resulted in incorrect IBDQ data being presented in the publication. The error does not affect the overall conclusions regarding IBDQ as the difference between the corrected and erroneous numbers is, in general, small. The error was specific to IBDQ data; all other data have been reviewed and are correct as originally reported.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
- Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
- Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
- Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
- Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
